Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E36.51 EPS (ttm)1.51 Insider Own0.50% Shs Outstand2.62B Perf Week2.60%
Market Cap144.85B Forward P/E17.33 EPS next Y3.19 Insider Trans0.00% Shs Float2.60B Perf Month8.62%
Income3.98B PEG1.97 EPS next Q0.48 Inst Own15.60% Short Float4.55% Perf Quarter6.81%
Sales27.58B P/S5.25 EPS this Y137.20% Inst Trans-1.05% Short Ratio11.70 Perf Half Y-4.84%
Book/sh5.50 P/B10.04 EPS next Y25.15% ROA6.20% Target Price63.60 Perf Year3.20%
Cash/sh2.96 P/C18.65 EPS next 5Y18.50% ROE29.20% 52W Range46.48 - 64.94 Perf YTD10.44%
Dividend1.40 P/FCF74.05 EPS past 5Y1.70% ROI12.20% 52W High-14.98% Beta0.56
Dividend %2.54% Quick Ratio0.70 Sales past 5Y1.50% Gross Margin79.00% 52W Low18.78% ATR0.88
Employees76100 Current Ratio0.90 Sales Q/Q15.20% Oper. Margin21.20% RSI (14)68.57 Volatility1.15% 1.28%
OptionableYes Debt/Eq1.40 EPS Q/Q99.20% Profit Margin14.40% Rel Volume0.51 Prev Close55.05
ShortableYes LT Debt/Eq1.24 EarningsApr 30 BMO Payout90.40% Avg Volume10.09M Price55.21
Recom1.50 SMA204.21% SMA508.58% SMA2005.04% Volume5,196,007 Change0.29%
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
May-16-21 11:09PM  
08:03PM  
12:17PM  
03:22AM  
02:04AM  
May-15-21 08:05AM  
01:37AM  
May-14-21 03:29PM  
02:40PM  
01:40PM  
11:02AM  
10:00AM  
02:00AM  
May-13-21 02:27PM  
02:16PM  
12:36PM  
12:18PM  
10:30AM  
10:09AM  
07:00AM  
06:56AM  
06:33AM  
06:18AM  
May-12-21 09:01PM  
05:37PM  
02:14PM  
02:01PM  
11:05AM  
09:39AM  
07:55AM  
07:24AM  
05:46AM  
04:01AM  
04:00AM  
May-11-21 08:54PM  
08:00PM  
08:00PM  
03:39PM  
03:23PM  
02:09PM  
12:46PM  
11:17AM  
10:51AM  
09:25AM  
09:13AM  
09:11AM  
09:10AM  
08:45AM  
08:41AM  
06:20AM  
05:58AM  
03:50AM  
03:12AM  
May-10-21 08:00PM  
05:32PM  
04:55PM  
04:44PM  
01:53PM  
12:12PM  
11:58AM  
11:40AM  
11:37AM  
11:11AM  
11:07AM  
10:51AM  
09:02AM  
09:00AM  
09:00AM  
08:51AM  
08:21AM  
08:14AM  
07:15AM  
06:48AM  
05:13AM  
04:48AM  
04:20AM  
04:06AM  
May-09-21 03:54PM  
08:27AM  
07:32AM  
06:30AM  
05:51AM  
May-08-21 08:00PM  
01:46PM  
10:44AM  
06:02AM  
May-07-21 06:23PM  
06:01PM  
03:56PM  
02:04PM  
01:54PM  
11:57AM  
11:00AM  
10:44AM  
10:34AM  
08:27AM  
08:15AM  
07:41AM  
07:24AM  
07:00AM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; and Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.